Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Comparison of the Effects of Dexmedetomidine and Remifentanil on Seizure Duration, Hemodynamics, and Recovery Time in Electroconvulsive Therapy

J ECT. 2025 May 20. doi: 10.1097/YCT.0000000000001161. Online ahead of print.

ABSTRACT

OBJECTIVES: Electroconvulsive therapy (ECT) is an important treatment method that is widely used in psychiatric conditions resistant to pharmacological treatments.

METHODS: This prospective, randomized study included 100 patients undergoing ECT. Group D received dexmedetomidine and propofol, while group R received remifentanil and propofol. In this study, key parameters such as seizure duration, hemodynamic changes, and recovery time were analyzed.

RESULTS: The investigation revealed no statistically significant differences between the groups with regard to mean age, gender distribution, or seizure duration (P > 0.05). Subsequent to induction, group R exhibited statistically significantly lower systolic blood pressure, diastolic blood pressure, and mean arterial pressures in comparison to group D (P < 0.05). Conversely, heart rate, systolic blood pressure, diastolic blood pressure, and mean arterial pressure levels in group R were found to be statistically significantly higher than in group D (P < 0.05). The recovery time in group D was found to be statistically significantly longer than in group R (P < 0.05).

CONCLUSIONS: Dexmedetomidine provides superior hemodynamic stability, while remifentanil ensures faster recovery. Dexmedetomidine has been shown to be more advantageous in terms of hemodynamic stability, while remifentanil has been demonstrated to result in shorter recovery times. Clinicians should tailor anesthetic choices based on patient profiles and therapeutic goals.

PMID:40424541 | DOI:10.1097/YCT.0000000000001161

Document this CPD

AI-Assisted Evidence Search

Share Evidence Blueprint

QR Code

Search Google Scholar

close chatgpt icon
ChatGPT

Enter your request.

Psychiatry AI: Real-Time AI Scoping Review (RAISR4D)